公开(公告)号：US20210080467A1

公开(公告)日：2021-03-18

申请号：US16971386

申请日：2019-02-20

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Céline COLACIOS VIATGÉ ,  Caroline IMBERT ,  Bruno SEGUI ,  Nicolas MEYER ,  Laurence LAMANT-ROCHAIX ,  Thierry LEVADE ,  Nathalie ANDRIEU-ABADIE

IPC分类号： G01N33/574 ,  G01N33/533

摘要： Immune checkpoint inhibitors (ICI) have revolutionized therapy for advanced cancer, however many patients still do not respond to treatment. However, the efficacy and effectiveness of these therapies varies greatly across individual patients and among different tumour types. A substantial unmet need is thus the development of biomarkers of response to ICI, in order to identify, before initiation of treatment, which patients are likely to experience a response to and clinical benefit from such treatments. Here, the inventors analyzed SPHK1 mRNA in tumor biopsies by in situ hybridization using the RNAscope technology in a cohort of 32 patients suffering from metastatic melanoma. They showed that elevated expression of SPHK1, encoding sphingosine kinase 1 (SK1), which produces the oncometabolite sphingosine-1-phosphate (S1P) is associated with a poor survival in metastatic melanoma patients treated with to the well-known immune-checkpoint inhibitor anti-PD-1 antibody. Accordingly, the present invention relates to the use of SK1 as biomarker for predicting response to immune-checkpoint inhibitors.

公开(公告)号：US20210145977A1

公开(公告)日：2021-05-20

申请号：US17146798

申请日：2021-01-12

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Thierry LEVADE ,  Bruno SEGUI ,  Nicolas MEYER ,  Céline COLACIOS VIATGÉ ,  Nathalie ANDRIEU-ABADIE ,  Florie BERTRAND

IPC分类号： A61K47/68 ,  C07K16/24 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00

摘要： The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNFα blocking agent to a subject in combination with the immune checkpoint inhibitor.

公开(公告)号：US20210040215A1

公开(公告)日：2021-02-11

申请号：US17036763

申请日：2020-09-29

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  Université Toulouse III - Paul Sabatier ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Thierry LEVADE ,  Nicolas MEYER ,  Céline COLACIOS VIATGÉ ,  Caroline IMBERT ,  Nathalie ANDRIEU-ABADIE ,  Bruno SEGUI

IPC分类号： C07K16/28 ,  A61K31/133 ,  G01N33/574 ,  G01N33/569 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395 ,  A61K31/4535 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/415 ,  A61K31/40 ,  A61K31/137

摘要： The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

公开(公告)号：US20190038763A1

公开(公告)日：2019-02-07

申请号：US16073141

申请日：2017-01-27

申请人： INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Thierry LEVADE ,  Bruno SEGUI ,  Nicolas MEYER ,  Céline COLACIOS VIATGÉ ,  Nathalie ANDRIEU-ABADIE ,  Florie BERTRAND

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/24 ,  C07K16/28

摘要： The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNFα blocking agent to a subject in combination with the immune checkpoint inhibitor.

公开(公告)号：US20190031757A1

公开(公告)日：2019-01-31

申请号：US16073080

申请日：2017-01-27

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET SANTE ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Thierry LEVADE ,  Nicolas MEYER ,  Céline COLACIOS VIATGÉ ,  Caroline IMBERT ,  Nathalie ANDRIEU-ABADIE ,  Bruno SEGUI

IPC分类号： C07K16/28 ,  A61P35/00

CPC分类号： C07K16/2818 ,  A61K31/133 ,  A61K31/137 ,  A61K31/40 ,  A61K31/415 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4535 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  G01N33/56972 ,  G01N33/574 ,  G01N2333/70517 ,  G01N2800/52 ,  A61K2300/00

摘要： The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.